

In the Claims

Claims 1-32 (Cancelled)

Claim 33 (Currently amended): An immunogenic composition comprising ~~one or more plasmid DNA coacervated with chitosan, wherein said one or more plasmid DNA encode an M2 respiratory syncytial virus (RSV) antigen and at least three RSV antigens selected from the group consisting of F, G, M, SH, NS1, NS2, N, and P nanospheres, wherein said nanospheres comprise plasmid DNA coacervated with chitosan, and wherein said plasmid DNA encode respiratory syncytial virus (RSV) antigens M2, F, G, M, SH, NS1, NS2, N, and P.~~

Claims 34-36 (Cancelled)

Claim 37 (Withdrawn): A method for raising an immune response in a host against RSV, comprising administering to the host an immunoeffective amount of the immunogenic composition of claim 33.

Claim 38 (Withdrawn): The method of claim 37, wherein said administering is oral or intranasal.

Claim 39 (Withdrawn): The method of claim 37, wherein said administering does not induce airway hyperreactivity.

Claim 40 (Withdrawn): The method of claim 37, wherein the immunoeffective amount is administered in a single dose.

Claim 41 (Withdrawn): The method of claim 37, wherein the immunoeffective amount is about 1 mg/kg host weight.

## Claims 42-44 (Cancelled)

Claim 45 (Withdrawn-currently amended): A method of making the immunogenic composition of claim 33, comprising cloning cDNA encoding the RSV antigens in one or more plasmids to form the one or more plasmid DNA; and coacervating said one or more plasmid DNA with the chitosan coacervating the plasmid DNA with chitosan to form the nanospheres.

## Claims 46-48 (Cancelled)

Claim 49 (Withdrawn-currently amended): The method of claim 45, wherein the one or more plasmids are pVAX plasmids further comprising cloning cDNA encoding the RSV antigens in plasmids to form the plasmid DNA.

Claim 50 (Currently amended): An immunogenic composition comprising one or more plasmid DNA coacervated with chitosan, wherein said one or more plasmid DNA encode an M2 respiratory syncytial virus (RSV) antigen, and at least three RSV antigens are selected from the group consisting of F, G, M, SH, NS1, NS2, N, and P, nanospheres, wherein said nanospheres comprise plasmid DNA coacervated with chitosan, wherein said plasmid DNA encode respiratory syncytial virus (RSV) antigens M2, F, G, M, SH, NS1, NS2, N, and P, and wherein said immunogenic composition is an inhalant.

## Claims 51-53 (Cancelled)